Veterinary Anti-infectives Market Report 2026

Veterinary Anti-infectives Market Overview

• Veterinary Anti-infectives market size has reached to $6.02 billion in 2025 • Expected to grow to $9.53 billion in 2030 at a compound annual growth rate (CAGR) of 9.7% • Growth Driver: Pet Ownership Fuels Growth In Veterinary Anti-Infectives Market • Market Trend: Digital Prescription And Delivery Platforms Expanding Anti infective Access • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Veterinary Anti-infectives Market?

The term veterinary anti-infective refers to a broad category where animals are cared for by providing both illness prevention and cure approaches. They are used in veterinary medicine to ensure the health and well-being of livestock and pets, as well as to manage disease outbreaks in animal populations. The main types of drugs classes in veterinary anti-infectives are antimicrobial agents, antiviral agents, antifungal agents, and others. Antimicrobial agents are natural or synthetic substances that work by killing or inhibiting the growth of microorganisms such as bacteria, fungi, and algae. The various species types involved are livestock animals and companion animals that are administered through oral, parenteral, and topical modes of administration and are distributed through veterinary hospitals, veterinary clinics, pharmacies, and other distribution channels.

What Is The Veterinary Anti-infectives Market Growth Forecast?

The veterinary anti-infectives market size is expected to see strong growth in the next few years. It will grow to $9.53 billion in 2030 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to rising demand for precision veterinary medicines, growing adoption of antiviral and antifungal agents, increasing focus on preventive healthcare, expansion of veterinary hospitals and pharmacies, development of immune modulators and advanced disinfectants. Major trends in the forecast period include increasing use of antibiotics and antimicrobial agents, rising adoption of vaccines and antiviral medications, growing awareness of animal disease prevention, expansion of companion animal healthcare market, rising demand for topical and systemic antifungal treatments.

Global Veterinary Anti-infectives Market Segmentation

1) By Drug Class: Antimicrobial Agents, Antiviral Agents, Antifungal Agents, Other Drug Classes 2) By Species Type: Livestock Animals, Companion Animals 3) By Mode Of Administration: Oral, Parenteral, Topical 4) By Distribution Channel: Veterinary Hospitals, Veterinary Clinics, Pharmacies, Other Distribution Channels Subsegments: 1) By Antimicrobial Agents: Antibiotics, Antiseptics 2) By Antiviral Agents: Vaccines, Antiviral Medications 3) By Antifungal Agents: Topical Antifungals, Systemic Antifungals 4) By Other Drug Classes: Parasiticides, Immune Modulators, Disinfectants

What Is The Driver Of The Veterinary Anti-infectives Market?

An increase in pet ownership is expected to propel the growth of the veterinary anti-infectives market going forward. Pet ownership refers to owning a dog, cat, or other domestic pet at home. Pets are being adopted as increasing number of the young population are considering them as part of their family, some owners are adopting them for their compassion, loyalty and the to prevent loneliness. Veterinary anti-infectives help pet ownership by preventing and treating infections in pets, ensuring their health and reducing the risk of illness for both animals and owners. For instance, in 2023, according to the Shelter Animals Count, a US-based non-governmental organization, 177,000 additional dogs and cats were in the animal sheltering system nationwide compared to the same time in 2022. Therefore, an increase in pet ownership is driving the demand for veterinary anti-infectives industry.

Key Players In The Global Veterinary Anti-infectives Market

Major companies operating in the veterinary anti-infectives market are Bayer AG, C. H. Boehringer Sohn AG & Co. KG, Ceva Santé Animale, Elanco Animal Health Incorporated, Zoetis Inc., Vetoquinol S. A., Merck & Co., Phibro Animal Health, Aspen Veterinary Resources Ltd., Bimeda Animal Health Limited, Dechra Pharmaceuticals Plc, Intervet International B. V., Oceanic Pharmachem Pvt. Ltd., Virbac Ltd., Indian Immunologicals Ltd. (IIL), Norbrook Laboratories Ltd., Ashish Life Science Pvt. Ltd., Kyoritsu Seiyaku Corporation, Tianjin Ringpu Bio-Technology Co. Ltd., HIPRA, Zydus Animal Health and Investments Limited, China Animal Husbandry Group, ZOOVETVARU Ltd., Magnum Veterinaaria Ltd., Inovet (V. M. D. nv/sa), Chanelle Pharmaceuticals Manufacturing Ltd., Huvepharma Inc., Veyx Pharma GmbH, Biovet Pvt. Ltd., Laboratorios Ovejero SA, Laboratorios Syva S. A.

Global Veterinary Anti-infectives Market Trends and Insights

Major companies operating in the market are using advanced technologies to sustain their position in the veterinary anti-infectives market. Advanced technologies refer to innovative methods and tools that improve the prevention, diagnosis, and treatment of infections in animals, enhancing effectiveness and safety. For instance, in May 2025, Amazon.com Inc., a US based e commerce and pharmacy services provider, launched expanded pet prescription medication offerings in partnership with Strategic Pharmaceutical Solutions Inc. (Vetsource), a US-based leading veterinary technology and pharmacy platform, that allow customers to order veterinarian approved anti infective and other prescriptions online, provide delivery typically within two to six days, and simplify refill approvals through digital checkout integration and veterinarian verification. This innovation broadens access and enhances client engagement but may require careful integration with clinical workflows and adherence to regulatory standards.

What Are Latest Mergers And Acquisitions In The Veterinary Anti-infectives Market?

In April 2024, Virbac S.A., a France based provider of veterinary pharmaceuticals, vaccines, anti infectives, and animal health products for companion animals and livestock, acquired Sasaeah Pharmaceutical Co. Ltd. for an undisclosed amount. With this acquisition, Virbac expanded its geographic footprint and strengthened its veterinary anti infectives and broader pharmaceutical portfolio, particularly in the cattle segment, by leveraging Sasaeah’s established manufacturing and R&D capabilities in Japan and Vietnam. Sasaeah Pharmaceutical Co. Ltd. is a Japan-based provider of veterinary animal health products, including vaccines, anti infectives, and pharmaceutical treatments across major species, enhancing Virbac’s competitive position in the global veterinary anti infectives market.

Regional Outlook

North America was the largest region in the veterinary anti-infectives market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Veterinary Anti-infectives Market?

The veterinary anti-infectives market consists of revenues earned by entities by providing antibacterial that are used to prevent and treat animal diseases such as infections. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.